Table 1.

Estrogen Receptor α (ERα) expression and prognostic value in serous ovarian carcinoma.

REFERENCE	EXPRESSION % POSITIVE	IHC CUT-OFF	% HGSC	PREDICTIVE	COMMENTS
3	81%	≥50% (strong positivity) 1–50% (weak positivity)	59%	No	60% strong positivity. Confounding factors controlled for: Age, stage, grade, completeness of cytoreduction, CA125.
4	43%	≥10%	61.7%	Yes	Positivity associated with good prognosis. Confounding factors controlled for: Age, stage, grade, completeness of cytoreduction.
5	50%	mRNA expression.	–	–	10 patients with serous carcinoma. 50% positive. Controlled for the following confounding factors: Stage, grade.
6	43%	>50%	86%	Yes	95% stage II. Positivity associated with good prognosis. No multivariate analysis.
7	32%	>10%	100%	Yes	32% positive. Positivity associated with better OS and PFS. Controlled for confounding factors: Age, stage, grade, lymph node status, ERβ receptor status.
8	54%	Semiquantitative (No or weak staining versus strong staining)	100%	No	41% considered positive. Trend for good prognosis of ER positivity in younger patients. Univariate analysis negative. No multivariate analysis.
10	60.4%	>10 fmol/mg (Biochemical method)	0%	Yes	ER positivity associated with worse survival. All patients had optimally cytoreduced stage III cystadenocarcinomas. Controlled for confounding factors: Age, grade, PR status.

Abbreviations: OS, Overall Survival; PFS, Progression Free Survival; IHC, Immunohistochemistry; HGSC, High Grade Serous Carcinoma; CA125, Cancer Antigen 125.